110 related articles for article (PubMed ID: 31537582)
21. Pioglitazone, an agonist of PPARγ, reverses doxorubicin-resistance in an osteosarcoma patient-derived orthotopic xenograft model by downregulating P-glycoprotein expression.
Higuchi T; Sugisawa N; Miyake K; Oshiro H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Kline Z; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Biomed Pharmacother; 2019 Oct; 118():109356. PubMed ID: 31545293
[TBL] [Abstract][Full Text] [Related]
22. Pioglitazone improves visceral sensation and colonic permeability in a rat model of irritable bowel syndrome.
Nozu T; Miyagishi S; Nozu R; Takakusaki K; Okumura T
J Pharmacol Sci; 2019 Jan; 139(1):46-49. PubMed ID: 30522964
[TBL] [Abstract][Full Text] [Related]
23. A methodologic analysis of chemoprevention and cancer prevention strategies for gastrointestinal cancer.
Jankowski JA; Hawk ET
Nat Clin Pract Gastroenterol Hepatol; 2006 Feb; 3(2):101-11. PubMed ID: 16456576
[TBL] [Abstract][Full Text] [Related]
24. PPAR-γ agonist, pioglitazone, reduced oxidative and endoplasmic reticulum stress associated with L-NAME-induced hypertension in rats.
Soliman E; Behairy SF; El-Maraghy NN; Elshazly SM
Life Sci; 2019 Dec; 239():117047. PubMed ID: 31730865
[TBL] [Abstract][Full Text] [Related]
25. Peroxisome proliferator-activated receptor-gamma targeting nanomedicine promotes cardiac healing after acute myocardial infarction by skewing monocyte/macrophage polarization in preclinical animal models.
Tokutome M; Matoba T; Nakano Y; Okahara A; Fujiwara M; Koga JI; Nakano K; Tsutsui H; Egashira K
Cardiovasc Res; 2019 Feb; 115(2):419-431. PubMed ID: 30084995
[TBL] [Abstract][Full Text] [Related]
26. Interaction of epidermal growth factor with COX-2 products and peroxisome proliferator-activated receptor-γ system in experimental rat Barrett's esophagus.
Majka J; Wierdak M; Szlachcic A; Magierowski M; Targosz A; Urbanczyk K; Krzysiek-Maczka G; Ptak-Belowska A; Bakalarz D; Magierowska K; Chmura A; Brzozowski T
Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G375-G389. PubMed ID: 31928220
[TBL] [Abstract][Full Text] [Related]
27. [Preventing cancer of the upper respiratory and digestive tracts].
Verny A; Foulon C; Van Den Abele E
Rev Infirm; 2011 Dec; (176):43-4. PubMed ID: 22256530
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease.
Sato T; Hanyu H; Hirao K; Kanetaka H; Sakurai H; Iwamoto T
Neurobiol Aging; 2011 Sep; 32(9):1626-33. PubMed ID: 19923038
[TBL] [Abstract][Full Text] [Related]
29. Epidemiology, biology, and chemoprevention of aerodigestive cancer.
Lippman SM; Spitz M; Trizna Z; Benner SE; Hong WK
Cancer; 1994 Nov; 74(9 Suppl):2719-25. PubMed ID: 7954292
[TBL] [Abstract][Full Text] [Related]
30. Pioglitazone inhibits cancer cell growth through STAT3 inhibition and enhanced AIF expression via a PPARγ-independent pathway.
Tsubaki M; Takeda T; Tomonari Y; Kawashima K; Itoh T; Imano M; Satou T; Nishida S
J Cell Physiol; 2018 Apr; 233(4):3638-3647. PubMed ID: 29030979
[TBL] [Abstract][Full Text] [Related]
31. Safety and Preclinical Efficacy of Aerosol Pioglitazone on Lung Adenoma Prevention in A/J Mice.
Seabloom DE; Galbraith AR; Haynes AM; Antonides JD; Wuertz BR; Miller WA; Miller KA; Steele VE; Suen CS; O'Sullivan MG; Ondrey FG
Cancer Prev Res (Phila); 2017 Feb; 10(2):124-132. PubMed ID: 27993834
[TBL] [Abstract][Full Text] [Related]
32. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
[TBL] [Abstract][Full Text] [Related]
33. PPAR-γ agonist pioglitazone reduces microglial proliferation and NF-κB activation in the substantia nigra in the 6-hydroxydopamine model of Parkinson's disease.
Machado MMF; Bassani TB; Cóppola-Segovia V; Moura ELR; Zanata SM; Andreatini R; Vital MABF
Pharmacol Rep; 2019 Aug; 71(4):556-564. PubMed ID: 31132685
[TBL] [Abstract][Full Text] [Related]
34. Renal-Protective Effects of the Peroxisome Proliferator-Activated Receptor-γ Agonist Pioglitazone in ob/ob Mice.
Li Y; Xia T; Li R; Tse G; Liu T; Li G
Med Sci Monit; 2019 Mar; 25():1582-1589. PubMed ID: 30820023
[TBL] [Abstract][Full Text] [Related]
35. Activation of PPARγ Attenuates the Expression of Physical and Affective Nicotine Withdrawal Symptoms through Mechanisms Involving Amygdala and Hippocampus Neurotransmission.
Domi E; Caputi FF; Romualdi P; Domi A; Scuppa G; Candeletti S; Atkins A; Heilig M; Demopulos G; Gaitanaris G; Ciccocioppo R; Ubaldi M
J Neurosci; 2019 Dec; 39(49):9864-9875. PubMed ID: 31685649
[TBL] [Abstract][Full Text] [Related]
36. Study design for the prevention of aerodigestive tract cancers.
Moon TE
Adv Exp Med Biol; 1992; 320():105-9. PubMed ID: 1442274
[No Abstract] [Full Text] [Related]
37. The peroxisome proliferator-activated receptor gamma agonist pioglitazone improves nitric oxide availability, renin-angiotensin system and aberrant redox regulation in the kidney of pre-hypertensive rats.
Kvandova M; Barancik M; Balis P; Puzserova A; Majzunova M; Dovinova I
J Physiol Pharmacol; 2018 Apr; 69(2):. PubMed ID: 29980143
[TBL] [Abstract][Full Text] [Related]
38. Fixed-Dose Combinations of Pioglitazone and Metformin for Lung Cancer Prevention.
Seabloom DE; Galbraith AR; Haynes AM; Antonides JD; Wuertz BR; Miller WA; Miller KA; Steele VE; Miller MS; Clapper ML; O'Sullivan MG; Ondrey FG
Cancer Prev Res (Phila); 2017 Feb; 10(2):116-123. PubMed ID: 28052934
[TBL] [Abstract][Full Text] [Related]
39. Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: implications for chemoprevention.
Ondrey F
Clin Cancer Res; 2009 Jan; 15(1):2-8. PubMed ID: 19118026
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor gamma agonist treatment.
Grommes C; Landreth GE; Sastre M; Beck M; Feinstein DL; Jacobs AH; Schlegel U; Heneka MT
Mol Pharmacol; 2006 Nov; 70(5):1524-33. PubMed ID: 16887936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
